Last edition
News about "Samsung Bioepis"
Samsung Bioepis Launches First Biosimilar Product in Japan with Ustekinumab Therapy
Samsung Bioepis launches its ustekinumab biosimilar in Japan through a partnership with Nipro Corporation, expanding access to affordable treatments for chronic autoimmune diseases.
Samsung Bioepis | 21/05/2026 | By News Bureau
Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27
The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.
Samsung Bioepis | 08/05/2026 | By News Bureau | 142
Samsung Bioepis and ATLATL Sign MoU to Boost Early-Stage Biotech Innovation in Asia-Pacific
Samsung Bioepis partners with ATLATL to accelerate early-stage biotech innovation in Asia-Pacific, leveraging R&D expertise to support startups and advance breakthrough technologies.
Samsung Bioepis | 30/04/2026 | By News Bureau
Samsung Bioepis Starts Phase 1 Trial for Nectin-4 ADC SBE303
Samsung Bioepis launches Phase 1 trial of SBE303, a Nectin-4 targeting ADC, marking a key step in advancing its oncology pipeline and Antibody-Drug Conjugate development.
Samsung Bioepis | 16/04/2026 | By News Bureau
Samsung Bioepis Partners with Sandoz for Next-Gen Biosimilar Candidates
Samsung Bioepis has partnered with Sandoz to develop and commercialise up to five biosimilar candidates, including SB36 (vedolizumab), across global markets, excluding select Asian regions, strengthening its pipeline in immunology and oncology.
Samsung Bioepis | 19/03/2026 | By News Bureau | 102
Samsung Bioepis and Epis NexLab Partner G2GBIO to Develop Long-Acting Semaglutide
Samsung Bioepis and Epis NexLab have signed a research collaboration and licensing agreement with G2GBIO to develop novel assets, including long-acting semaglutide, using G2GBIO’s proprietary microsphere drug delivery technology.
Samsung Bioepis | 16/03/2026 | By News Bureau | 110
Samsung Bioepis Launches BYOOVIZ Biosimilar in Europe
Samsung Bioepis has completed the transfer of BYOOVIZ commercial rights from Biogen, making it the company’s fourth biosimilar directly marketed in Europe, with a pre-filled syringe launch planned for Q2 2026.
Samsung Bioepis | 03/01/2026 | By News Bureau | 153
Samsung Biologics has announced its financial results for the second quarter of fiscal year 2025, posting strong growth across both consolidated and standalone metrics.
Samsung Bioepis | 23/07/2025 | By Dineshwori | 1453
Samsung Bioepis Partners with Harrow for US Commercialisation of Ophthalmology Biosimilars
Following the transition of commercial rights from Biogen back to Samsung Bioepis, Harrow will assume full responsibility for the commercialisation of both BYOOVIZ and OPUVIZ biosimilars in the US.
Samsung Bioepis | 18/07/2025 | By Dineshwori | 317
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy